What Ki‑67 proliferation index is considered high in non‑Hodgkin lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ki-67 Proliferation Index Thresholds in Non-Hodgkin Lymphoma

A Ki-67 proliferation index >30% is considered high in non-Hodgkin lymphoma, particularly for mantle cell lymphoma (MCL), where this cutoff defines poor-risk disease with significantly worse outcomes regardless of age or treatment intensity. 1

Specific Cutoffs by Context

Mantle Cell Lymphoma (Most Established)

The evidence for MCL is the strongest and most clinically actionable:

  • >30% = High-risk/Poor prognosis: This is the validated cutoff used in the biologic MIPI (MIPI-b) scoring system, which has been prospectively validated across multiple treatment settings 1
  • 10-30% = Intermediate risk
  • ≤10% = Low-risk/Indolent: Associated with more indolent clinical course and may warrant watch-and-wait approach in selected cases with low tumor burden 2

The 30% threshold stratifies patients into groups with statistically significantly different outcomes (P <0.001) and is recommended as the standard cutoff for prospective clinical trial stratification 1.

Aggressive vs. Indolent NHL (General)

For broader NHL classification:

  • >45% = Aggressive lymphoma: This cutoff differentiates aggressive from indolent disease with 85% sensitivity for aggressive lymphomas and 82.8% specificity for indolent lymphomas (AUC = 0.877) 3
  • <45% = Indolent lymphoma: Found in 82.8% of indolent lymphomas 3

Diffuse Large B-Cell Lymphoma (DLBCL)

  • >70% = Poor prognosis: In DLBCL specifically, a 70% cutoff significantly discriminates good vs. bad prognosis (AUC = 0.65, P = 0.004) 3
  • 3-year survival: 75% with Ki-67 ≤70% vs. 56% with Ki-67 >70% (P = 0.015)
  • This cutoff is particularly useful when combined with low IPI scores (≤2) or bulky disease (>10 cm) 3

Historical High-Risk Threshold

  • >60% or >80%: Older studies identified these as markers of rapidly fatal disease with independent prognostic significance 4, 5, though these have been superseded by the more refined cutoffs above

Clinical Application Algorithm

For MCL patients:

  1. Obtain Ki-67 on diagnostic biopsy using standardized quantification methods
  2. Use 30% cutoff to stratify risk in combination with MIPI score
  3. Ki-67 >30% → consider more aggressive treatment regardless of age
  4. Ki-67 ≤10% with low tumor burden → consider watch-and-wait with close observation 2

For other NHL subtypes:

  1. Use 45% cutoff to distinguish aggressive from indolent behavior
  2. For DLBCL specifically, apply 70% cutoff for prognostic stratification
  3. Combine with clinical factors (IPI, tumor bulk, LDH) for treatment decisions

Important Caveats

Standardization is critical: Ki-67 quantification can vary significantly between pathologists and institutions. Central pathology review with standardized methods is strongly recommended, particularly for clinical trials 1. Poor specimen quality or bone marrow samples may limit accurate Ki-67 assessment 1.

Context matters: While Ki-67 is the most established biological risk factor in MCL 2, its prognostic value varies by lymphoma subtype. The mean Ki-67 ranges from 26.6% in indolent lymphomas to 97.6% in very aggressive lymphomas like Burkitt lymphoma (approaching 100%) 3, 6.

Independent prognostic factor: Ki-67 maintains independent prognostic significance even after adjusting for clinical factors like age, stage, LDH, and performance status in multivariate analyses 3, 4, 5.

References

1
Guideline

recommendations for clinical trial development in mantle cell lymphoma.

Journal of the National Cancer Institute, 2017

Related Questions

What does a Ki-67 (Proliferation Index) index of 20% with positivity in 80-90% of cells in follicular centers indicate on a pathology report?
How does Ki‑67 guide cancer treatment decisions?
What is Ki‑67 immunohistochemical staining?
Is globifer a non‑heme iron source, and does vitamin C increase its absorption?
What is the recommended initial management for a reproductive‑age woman with symptomatic uterine fibroids causing heavy menstrual bleeding and pelvic pain?
In a patient with a pancreatic head mass involving the portal vein and the superior mesenteric artery (SMA), is surgical resection still feasible?
What is the appropriate apixaban dosing for an 87-year-old patient with stage 4 chronic kidney disease?
What is the Rives‑Stoppa repair technique for ventral or incisional hernia?
What is the appropriate diagnostic and therapeutic approach for a pregnant patient with pyrexia of unknown origin (PUO)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.